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Abstract
Schizophreniaisahighlydisablingdisorderwhosecausesremaintobebetterunderstood,andtreatments have
tobeimproved.However,severalrecentadvanceshavebeenmadeindiagnosis,etiopathology,and treatment.
Whereas reliability of diagnosis has improved with operational criteria, including Diagnostic and Statistical
Manual of Mental Disorders, (DSM) Fifth Edition, validity of the disease boundaries remains unclearbecauseof
substantive overlaps with other psychotic disorders. Recent emphasis on dimensional approaches and
translationalbio-behavioralresearchdomaincriteriamayeventuallyhelpmovetowardaneuroscience-based
definition of schizophrenia. The etiology of schizophrenia is now thought to be multifactorial, with
multiplesmall-effectandfewerlarge-effectsusceptibilitygenesinteractingwithseveral environmentalfactors.
Thesefactorsmayleadtodevelopmentallymediatedalterationsinneuroplasticity, manifesting in a cascade of
neurotransmitter and circuit dysfunctions and impaired connectivity with an onsetaroundearlyadolescence.
Such etiopathological understanding has motivated a renewed search for novel pharmacological as well
as psychotherapeutic targets. Addressing the core features of the illness, such as cognitive deficits and
negative symptoms, and developing hypothesis-driven early interventions and preventive strategies are
high-priority goals for the field. Schizophrenia is a severe, chronic mental disorder and is among the
most disabling disorders in all of medicine. It is estimated by the National Institute of Mental Health
(NIMH) that 2.4 million people over the age of 18 in the US suffer from schizophrenia. This illness
typically begins in adolescence and derails the formative goals of school, family, and work, leading to
considerable suffering and disability and reduced life expectancy by about 20 years. Treatment out-
comes are variable, and some people are successfully treated and reintegrated (i.e. go back to work).
Despite the effort of many experts in the field, however, schizophrenia remains a chronic relapsing
and remitting disorder associated with significant impairments in social and vocational functioning
and a shortened lifespan. Comprehensive treatment entails a multi-modal approach, including psy-
chopharmacology, psychosocial interventions, and assistance with housing and financial sustenance.
Research to date suggests a network of genetic, neural, behavioral, and environmental factors to be
responsible for its development and course. This article aims to summarize and explain recent ad-
vancements in research on schizophrenia, to suggest how these recent discoveries may lead to a better
understanding and possible further development of effective therapies, and to highlight the paradigm
shifts that have taken place in our understanding of the diagnosis, etiopathology, and treatment.
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The concept of schizophrenia as a disease entity has
undergone major changes over the past century. Kraepelin
distinguished chronic psychoses from functional decline,
which he termed dementia praecox, and episodic psy-
choses, which he called the manic-depressive insanity [1].
Subsequent literature pointed to considerable sympto-
matic overlap between these disorders, leading to the
rather loosely defined, and therefore unreliable, diagnosis
ofschizoaffective disorder [2]. Overthe pastcentury, these
categories have—to a large extent—remained the same, as
summarized in the current classificatory systems:the DSM
and the International Classification of Diseases (ICD) [3].
A noteworthy recent development in psychiatry was the
release of the fifth edition of the DSM in 2013. Although
no major changes were made to the definitions of
schizophrenia and other psychotic disorders, efforts were
made to increase simplicity of diagnoses. First, the
Kraepelinian subtyping of schizophrenia into paranoid,
disorganized, catatonic, and undifferentiated type was
eliminated because of a lack of evidence supporting the
validityofthesedistinctions.Second,catatoniawasmoved
to become a specifier across diagnoses rather than a
schizophrenia subtype. Third, a more longitudinal
approach to this diagnosis was defined. Finally, the
previous emphasis on Schneider‘s[ 4 ]“first rank” symp-
toms (i.e. delusions of thought broadcast and thought
insertion)andbizarredelusionswaseliminated.Although
all this improved the easeof use of the criteria, the validity
of these boundaries remained largely in question.
Over the past two decades, it has become increasingly
clear that there are neurobiological [5], genetic [6], and
treatment response [7] overlaps between these disorders,
bringing into question the validity of these categories [8].
A dimensional approach to psychopathology and the
view that biological impairments may cut across cate-
gories have led to the recent introduction of the research
domain criteria (RDoC). RDoC [9] refers to a framework
of representing accruing information across molecular,
cellular, circuit, and behavioral domains agnostic to
symptom-based diagnoses. Although this approach is
still in its infancy, it might offer a useful framework for
future research that may yield a neuroscience-informed
classificatory system [8].
There has also been interest in defining schizophrenia
beyond the symptoms listed in the DSM, with recent
consideration of cognitive decline as a core feature with
psychosis considered by some as a later development
[10,11].Alongtheselines,there havealsobeensignificant
efforts to better understand and characterize schizophre-
nia at earlier stages of the illness with the concept of
schizophrenia prodome, which became of increasing
clinical interest [12]. Schizophrenia prodrome, some-
times referred to as ultra-high-risk state or psychosis risk
syndrome, is thought to be a spectrum of attenuated
positive and negative symptoms that individuals may
display several years to months before converting to
schizophrenia.
Recent research has begun to elucidate risk factors for
conversion to psychosis, including early impaired cogni-
tive (e.g. inattention, concentration difficulties) and social
functioning [13]. Even though not all risk factors are
currently known, approximately 35% of the individuals
with prodromal symptoms convert to schizophrenia
[14, 15]. The North American Prodromal Longitudinal
Study,alargemulticenterstudy,hasbeguntodemonstrate
substantive neuroanatomical [16], neurophysiological
[17], neurocognitive [18], and neurohormonal [19]
changes during the prodromal phase that may contribute
to the risk of schizophrenia [20].
Pathophysiology and etiology
Schizophreniahasasubstantialgeneticcomponent,witha
high heritability (up to 80%), indicating that about 80%
of the variation in the trait of schizophrenia may be
attributed to genetic factors [21]. Genome-wide associa-
tion studies (GWASs), which compare the genomes of
thousands ofhealthyandaffectedindividuals,havefound
several genes associated with increased risk of developing
schizophrenia, such as NRGN and ZNF804A [22, 23].
Recentresearchsuggeststhat geneticriskforschizophrenia
is composed of many common genetic alterations, each
with a small effect, along with a few uncommon genetic
alterations with a larger impact [24]. Additionally, genes
that confer risk for schizophrenia may also be associated
with bipolar disorder and other psychiatric disorders [25]
(Figure 1).
Various environmental factors may interact with suscept-
ibility genes to increase the risk of schizophrenia; these
interactions are the focus of an emerging area of
investigation called epigenetics. One of the few replicated
findings in this relatively new field is an interaction
between cannabis use and the AKT1 gene on the risk of
psychosis [26, 27]. Other findings in epigenetics that have
not yet been replicated include interactions between a
history of fetal hypoxia and hypoxia-related genes on
volume of the hippocampus [28] and interactions
between childhood trauma and variants of the serotonin
transporter [29] and COMT gene [27] on cognitive
functioning. Although epigenetics research has the poten-
tial to greatly impact clinical practice, few studies have
attempted to replicate findings. Among those studies
attempting replication, few have been able to confirm
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a need for larger sample sizes in this type of research [30].
Although early neurobiological theories of schizophrenia
largely focused on excessive dopamine, more recent
research reflects a more nuanced role of dopamine and
has pointed to the importance of other neurotransmitters
such as GABA and glutamate. Recent animal models [31]
andgeneticstudiesofhumans[32] suggestthat hypofunc-
tion of the N-methyl-D-aspartate (NMDA) glutamatergic
receptor may underlie schizophrenia. Glutamate models
of schizophrenia may provide an additional explanation
to the dopaminergic models for the cognitive symptoms
of this illness and may ultimately yield novel pharmaco-
logical treatment approaches [33].
Neuropathology research indicates that schizophrenia is
characterized by abnormal maturation of prefrontal
networks during late adolescence and early adulthood,
likely due to excessive pruning of synapses and dendritic
spines [34, 35]. Pre- and post-synaptic abnormalities in
inhibitory neurons such as the parvalbumin interneuron
may disturb these critical neurodevelopmental processes
[36]. Recent research using optogenetics indicates that
parvalbumin interneurons may influence gamma oscil-
lations, which in turn are associated with cognitive
function [37]. Myelination (another critical neurodeve-
lopmental process) is also abnormal in schizophrenia, as
shown by post-mortem studies demonstrating reduced
expression of myelin basic protein in cortical regions
[38]. Disturbances in both myelination and the inhibi-
tory control of synaptic pruning may contribute to
cognitive deficits in schizophrenia [39]. These recent
advances in neuropathology build upon previous post-
mortem research demonstrating reduced neuropil, but
not a reduced number of neurons, in the brains of adults
with schizophrenia [40].
Recent studies have shown compelling evidence that
neuropathological changes in schizophrenia might set in
during the critical period of adolescence, proximal to the
onsetofpsychosis.Gray-matterdeclinesappeartooccurin
the early phase of schizophrenia and may be related to
pooreroutcomes.Theearlyphaseofpsychosismayalsobe
associated with elevations in presynaptic dopamine turn-
over[41] as well asincreases in glutamatergicactivity[42].
These observations highlight the importance of early
recognition and intervention targeted to the pathophysio-
logical processes close to the onset of psychosis.
In the past several years, inflammation and oxidative
stress have re-emerged as potentially important aspects
of pathophysiology in a subset of affected individuals.
Multiple studies have demonstrated elevated levels of
cytokines and other signs of immune system activation
in individuals with psychosis [43, 44], and genetic
Figure 1. Etiology of schizophrenia
The multifactorial etiology of schizophrenia including a) rare genes that have a large effect, b) common genes that have a small effect, and c) the environmental
factors and gene-environmental interactions that confer risk for schizophrenia.
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nia and genes involved in the immune response [23].
Recent rodent work has observed that exposure to
infectious or inflammatory agents in utero can lead to
behavioral and neurobiological alterations resembling
those seen in schizophrenia [45]. Oxidative stress, which
is associated with inflammation, may also be elevated in
schizophrenia. For example, a recent meta-analysis of
studies on oxidative stress markers observed reduced
levels of the anti-oxidant red blood cell superoxide
dismutase in schizophrenia [46].
Additionally, some recent work has focused on auto-
immune dysfunction as a cause of psychosis. For
example, anti-NMDA-receptor encephalitis is a poten-
tially treatable but under-diagnosed cause of psychosis
that results from the production of antibodies against
NMDA receptors [47]. A number of young individuals
presenting with their first episode of psychosis may have
detectable auto-antibodies against this receptor or other
neuronal proteins, such as voltage-gated potassium
channels [48]. In addition, epidemiological data suggest
a bi-directional association between psychosis and some
common autoimmune diseases: individuals with one
type of illness are at greater risk of developing the other
type [49]. The potential therapeutic applications of these
findings are being actively explored.
Various forms of imaging research have been critical in
advancing our understanding of the neurobiology of
schizophrenia. Studies have reported subtle structural
alterations,including enlargementofthethirdandlateral
ventricles, slight reductions in whole-brain gray matter
volume, and slight reductions in the volumes of
temporal,frontal,andlimbicregions[50,51].Functional
imaging studies have observed reduced activation of the
dorsolateral prefrontal cortex during tasks of executive
function [52] and abnormalities of limbic system
activation during tasks involving emotional stimuli
[53]. In addition, studies using diffusion tensor imaging,
a method of visualizing white matter, have found
evidence of white matter changes in frontal and temporal
lobes that would imply decreased connectivity among
these regions [54]. Together, these findings support the
conceptualization of schizophrenia as a disorder of brain
connectivity [55]. Studies in the past few years have used
various forms of network analysis to uncover decreased
regional connectivity in both first-episode schizophrenia
[56] and the broader psychotic spectrum.
The next major challenge is to translate neuroimaging
findings into the clinical setting. Consequently, recent
research has started to integrate various imaging mod-
alitieswithgenetic,electrophysiological,andclinicaldata
to identify biomarkers, which may eventually be relevant
for clinical diagnosis and management.
Pharmacological treatments in schizophrenia
Antipsychotic drugs have been the mainstay of schizo-
phrenia treatment since the introduction of chlorproma-
zine, focusing on decreasing the frequency and severity of
psychotic episodes as well as improving the functional
capacity of individuals with schizophrenia [57]. However,
adverse effects and suboptimal outcomes associated with
first-generation antipsychotics (FGAs) led to the develop-
ment of second-generation antipsychotics (SGAs), which
due to their 5HT-2A antagonism are generally associated
with reduced extrapyramidal symptoms (EPSs) as com-
pared with FGAs [58]. However, there is controversy
concerning the categorization of FGA and SGAs; some
literaturedifferentiatesthembasedontheirabilitytocause
EPSs, whereas other studies base it on their antagonism of
the dopamine D-2 receptors [59, 60]. The first and most
efficacious SGA for the treatment of refractory schizo-
phrenia, clozapine, is limited by the risk of agranulocy-
tosis, which necessitates the use of periodic monitoring of
blood cell counts. EPSs are lowest with clozapine and
highest with haloperidol. All drugs except haloperidol,
ziprasidone, and lurasidone produce more weight gain,
with olanzapine and clozapine producing the greatest
weightgain.Prolactinelevationishighestwithrisperidone
and paliperidone. All drugs, except for amisulpride,
paliperidone,sertindole,andiloperidone,are significantly
more sedating than placebo [61].
Several large-scale investigations suggest no clear super-
iority of SGAs over FGAs among first-episode patients [62]
or chronic patients [63] in regard to positive, cognitive or
social outcomes [64]. Furthermore, both FGAs and SGAs
do not sufficiently target negative symptoms (with only
olanzapine and asenapine showing moderate effects
[65-67]) and sometimes insufficiently treat positive
symptoms [68, 69]. Clozapine seems to be the most
effective medicine, whereas the effectiveness of olanzapine
and risperidone over other antipsychotics remains con-
troversial [61, 70-72]. In terms of relapse prevention, SGAs
have a modest benefit compared with FGAs [73]. Newer
antipsychotics such as asenapine, iloperidone, lurasidone,
and paliperidone do not seem to be significantly better
than haloperidol [61], and for the treatment of refractory
schizophrenia, clozapine has been shown to be signifi-
cantlymoreefficaciousthanotheragents[74-78].However,
several studies suggest that olanzapine and risperidone
have greater efficacy over other antipsychotics, but this
remains controversial and more research is necessary in
this area. Additionally, amisulpride, olanzapine, clozapine,
paliperidone, and risperidone show significantly lower all-
causediscontinuationthanseveralotheragents[61,79-81].
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(PORT) summarized strong empirical support for both
FGAs and SGAs in acute and maintenance treatment of
schizophrenia and for the use of clozapine for treatment-
resistant positive symptoms, hostility, and suicidal beha-
viors [82].
Research over the past decade further investigated agents
that stimulate the NMDA glutamate receptor, including
partial and full agonists at the glycine site and glutamate
2/3 receptor agonists, and found that they may ameliorate
negative symptoms with some success if used in conjunc-
tion with antipsychotics [83]. The PORT concludes,
however, that there is still limited information on the
use of adjunctive pharmacological agents as well as the
treatment of co-occurring substance abuse [82]. None of
the pharmacological agents to date effectively ameliorate
cognitive deficits, which are a core feature of schizophre-
nia; larger and more rigorous studies are needed to
examine the potential pro-cognitive effects of medications
that impact dopaminergic, nicotinergic, glutamatergic,
GABAergic, and other novel targets [84].
Long-acting injectable antipsychotics are helpful in
treating patients with poor medication adherence and
have more controlled distributions in the body; for these
reasons, they are superior to oral antipsychotics in
preventing hospitalizations [85] and may foster a better
therapeutic alliance. Both FGA (haloperidol and fluphe-
nazine) and SGA (risperidone, paliperidone, olanzapine,
and aripiprazole) medications are now available as long-
acting preparations. Recent preliminary investigations
suggest a therapeutically beneficial response to dose
reductionandalternatedaydosing[86]intheearlystages
of remitted first-episode psychosis. However, more
research is needed to confirm these observations [87].
Recent advances in the understanding of schizophrenia
have restored interest in inflammatory and oxidative stress
pathways as the pathogenesis for a subset of patients.
Research on human and animal models supports this new
insight [88-93]. In a review by Sommer et al., 26 double-
blind randomized controlled trials reported on the efficacy
of anti-inflammatory agents such as aspirin, celecoxib,
davunetide, fatty acids (eicosapentaenoic acids and doc-
osahexaenoic acids), estrogens, minocycline, and antiox-
idants such as N-acetylcysteine (NAC) as treatment
augmentation for schizophrenia [94]. Aspirin, estrogens,
and NAC showed significant effects; in contrast, celecoxib,
minocycline, davunetide, and fatty acids showed no
significant difference [95]. Whereas more research is
neededto investigatethe therapeutic effects of both current
and novel anti-inflammatory agents, current evidence does
suggest a benefit in treating inflammation.
Pharmacogenomics is a growing field in the treatment of
schizophreniaandcanbringthefieldofpsychiatrycloserto
achieving evidence-based personalized medicine with the
goals of predicting better treatment response and reducing
medication-induced side effects. For example, polymorph-
isms in the serotonergic system are associated with the
efficacy of clozapine and risperidone, dopamine D3
receptor polymorphisms are associated with response to
clozapine and olanzapine, and D2 variants are associated
with the efficacy of risperidone [96]. As for side effects, the
serotonergic system (HTR2C) and hypothalamic leptin-
melanocortin genes (MC4R) can predict antipsychotic-
induced weight gain [97, 98], cytochrome P450 (CYP2D6)
and dopamine receptor variants are associated with tardive
dyskinesia [96, 99], and major histocompatibility complex
(human leukocyte antigen [HLA]) markers have been
consistentlyfoundtobeassociatedwithclozapine-induced
agranulocytosis. However, despite progress made in
pharmacogenomics, the field has encountered obstacles
such as replication inconsistencies, small study sizes, and
lack of randomized control trials.
Psychosocial treatments
Antipsychotic medications are a necessary but not
sufficient treatment for schizophrenia. The broad objec-
tives of treatment should be reducing the frequency and
severity of episodes of psychotic exacerbation as well as
improving the functional capacity and quality of lives of
the individuals afflicted with the illness. Thus, in tandem
with research over the past decades, the urgently needed
multimodal care has continued to evolve. Psychoanalytic
treatments beginning in the early 20th century seemed to
insufficiently address the burden caused by the illness. In
the early ‘60s, major role therapy and family psychoedu-
cation were introduced based on the interpersonal and
family theories of psychosis. With further research in the
field and increased knowledge about the nature of the
specific deficits (cognitive, social, and affective), more
disease-specific psychotherapies started to develop in the
‘80s and ‘90s. These therapies target both pathophysiol-
ogy and other core manifestations of the disease.
The PORT recently provided an extensive summary of the
current evidence-based psychosocial treatment [100].
Cognitive behavioral therapy(CBT) isbased onthe theory
that the way we interpret events has cognitive, emotional,
and behavioral consequences, which lead to the creation
and maintenance of unhelpful responses. CBT has been a
successful approach for other mental illnesses such as
depression [101] and anxiety [102]. More recently, CBT
has been applied to the treatment of positive as well as
negativesymptoms.ResearchshowsthatCBTcanimprove
positive symptoms [103, 104] but is less consistent with
the improvement of negative symptoms [105, 106].
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the short term (i.e. more than 12 months) [107].
Social skills training (SST) is based on a behavioral
model that targets the improvement of a person‘s ability
to function skillfully in social situations (i.e. interac-
tions). SST has emerged among the possible treatments
for schizophrenia [108] to address social skill deficits
primary to developmental derailments but also second-
ary due to both positive and negative symptoms [109].
SST has been found to improve both positive and
negative symptoms [106], and some of the improve-
ments may persist at follow-up [110].
Family therapy is based on a model that suggests that
problematic behaviors are maintained and created by
patterns in systems (i.e. proximal or distal family) [111].
System theory underlies the multifamily treatment
approach that includes coping recommendations, pro-
blem solving, crisis intervention, reduction of pathogenic
interactions such as high “expressed emotions” (e.g.
criticism, hostility), and (in its core) psychoeducation.
Psychoeducation enables not only the patient but also
the family and others to recognize early warning signs,
which is particularly important in an illness that shows
such high vulnerability to stress.
Assertive community treatment (ACT) offers a multi-
disciplinary approach that is usually combined with SST,
CBT, or any personal support. Teams include peer support
specialists and practitioners with expertise in psychiatry,
substance abuse treatment, and employment. Although
ACT reduces time in the hospital for mental illnesses in
general [112], it seems specifically to improve housing
stability [113] and reduce hospitalization rates, especially
in patients withhigher baselinehospitalizationrates[113].
Personal therapy was developed by Hogarty et al. [114]
on the basis of supportive psychotherapy. It is one of the
few approaches that was designed specifically for people
suffering from schizophrenia and combines SST with
some common elements of CBT. Personal therapy is
modeled to the phases of recovery; thus, it is a long-term
endeavor and seems to decrease the probability of
relapse [115].
Cognitive remediationtherapy (CRT) is a computer-based
intervention that was originally designed to improve
deficient cognitive abilities (e.g. attention, memory, and
executive function) in people with traumatic brain injury
[116] but since has proven to help in people with
depression [117], eating disorders [118], and schizoph-
renia [117]. Whereas CRT by itself has no effect on
improving negative symptoms [119], the combination of
CRT with SST, groups, and problem solving has been
foundtobepromising[120].Althoughpreliminaryresults
showed improvements in speed of processing, attention,
workingmemory,executivefunction,andsocialcognition
in a cognitive enhancement therapy (CET) comparedwith
a personal therapy group, rigorous validation is needed,
and the durability of these improvements remains to be
investigated.
For many patients the ability to resume work or school is
the ultimate goal. Thus, supported employment interven-
tions are of significant importance – the most commonly
studiedbeing the Individual Placement and Support (IPS)
[121] model. An important principle of the IPS model is
that minimal pre-vocational training is provided, and the
job itself becomes the primary training environment.
There is clear evidence that supported employment
strategies help return people with schizophrenia to work
[122], even for young people with their first episode of
psychosis [123]. A recent meta-analysis of a total of 11
studies found that competitive employment rates were
61%forpatientsand23%forcontrolsandthatabout30%
out of the 61% worked more than 20 hours weekly.
Supported employment further increased the duration of
employment (47% of the 52-week year) and the time of
onset of employment (approximately 10 weeks earlier
than controls). In conclusion, the effect sizes support the
effectiveness of evidence-based supported employment as
one of the most robust interventions.
Given the clinical heterogeneity of schizophrenia, it is
important to choose the right treatment for the right
patient; thus, although supportive treatment might
benefit all symptom domains, CBT may be particularly
beneficial for those with residual psychotic symptoms
and cognitive remediation, SST for those with cognitive
or social cognition deficits or both, and ACT for those at
risk for frequent hospitalizations or those who have had
recent homelessness. There is increasing emphasis on
tailoring psychotherapeutic interventions to the phase of
the illness(e.g.personaltherapy), since the primary goals
ofinterventionmightvaryacross phases.More researchis
needed, however, to examine active ingredients of the
therapeutic modalities that work and to identify the
synergistic effects of combinations of interventions that
are hypothesis-driven and cost-effective.
Conclusions and Future directions
In summary, although our understanding of the causes
and treatments of schizophrenia remains limited, several
important paradigm shifts have occurred. The diagnosis
of schizophrenia is still symptom-based, but increasing
amounts of data point to the large genetic and neurobio-
logical overlaps between psychotic, affective, and
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tions of these illnesses need to move toward more
evidence-based, valid, and biologically based categories
and dimensions. Pathophysiology is now seen as devel-
opmentally mediated alterations in neuroplasticity, man-
ifesting in a cascade of neurotransmitter and circuit
dysfunctions setting in around adolescence. Etiology is
now seen as an interaction between multiple genes of
small-effectandsomerarelarge-effectgenesandunknown
environmental factors. These observations may help
therapeutic interventions move beyond the current sole
focus on dopamine toward novel therapeutic targets such
as glutamate, GABA, and calcium channels. The focus of
intervention has expanded beyond relief of psychotic
symptoms alone toward restoring functionality by target-
ing dimensions such as cognitive deficits and negative
symptoms. Research is intensifying on the possible utility
of several evidence-based psychotherapy modalities in
combination with pharmacological approaches. Treat-
ments are still based on serendipitous discoveries from
decades ago, and the urgent need is to discover novel
interventions based on etiopathology. Finally, recent
incremental advances in understanding the etiopathology
have motivated vigorous prevention approaches in early
phases of the illness and early interventions with novel
pharmacological targets and plasticity-based treatments
such as cognitive remediation.
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